Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Center for International Blood and Marrow Transplant Research
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06859424CT.gov A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | — | Recruiting | — | — | — |
NCT07238712CT.gov Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor | — | Recruiting | — | — | — |
NCT06680661CT.gov ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abatacept Recombinant (this asset) | Center for International Blood and Marrow Transplant Research | P2 | CCC · 53 |
| Cyclophosphamide | City of Hope Medical Center | P3 | BBB |
| Nilotinib | Novartis Pharmaceuticals | P4 | BBB |
| Sargramostim | Virginia Commonwealth University | P2 | BBB |
| Romidepsin | Center for International Blood and Marrow Transplant Research | P2 | BBB |
| Therapeutic Allogeneic Lymphocytes | University of Chicago | P2 | BBB |
| Alemtuzumab | Diane George | P2/3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
| Imatinib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Chronic Myeloid Leukemia cohort
Other indications for Abatacept Recombinant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P3 | BB · 68 |
| Primary Biliary Cholangitis | — | P4 | BB · 66 |
| Acute Biphenotypic Leukemia | — | P3 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Abatacept Recombinant in Chronic Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/abatacept-recombinant-chronic-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →